Home Visit
Upload
AFB Drug Susceptibility Panel Comprehensive Panel 13 Drugs By MGIT - Pure Culture
Also known as: AFB Drug Susceptibility Panel - Comprehensive (13 drugs), Pure Culture
No special precautions
Sample Type
Blood
Recommended for
Male, Female
Report
Within 24 Hours
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
AFB Drug susceptibility - Comprehensive 13 drugs panel Overview
The "AFB Drug susceptibility - Comprehensive 13 drugs panel by MGIT - Pure Culture" test is a highly comprehensive and essential diagnostic tool for tuberculosis (TB) treatment. Using the MGIT (Mycobacteria Growth Indicator Tube) method on pure cultures of Mycobacterium tuberculosis (MTB) Complex, this test assesses the drug susceptibility of MTB to thirteen anti-tuberculosis drugs, offering an extensive range of treatment options. The panel includes first-line drugs such as Streptomycin, Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide, along with second-line drugs like Kanamycin, Ethionamide, PAS (Para-AminoSalicylic Acid), Ofloxacin, Capreomycin, Moxifloxacin, Amikacin, and Clofazimine. This comprehensive combination of drugs allows clinicians to gain a thorough understanding of the drug susceptibility patterns of the MTB Complex, including resistance to multiple drugs. The clinical utility of this test is immense as it provides critical information to healthcare professionals for formulating personalized and effective treatment regimens for TB patients. By evaluating drug susceptibility to an extensive range of drugs, this test enables the selection of appropriate and tailored drug combinations, optimizing patient care and increasing the chances of successful TB treatment. Overall, the AFB Drug susceptibility - Comprehensive 13 drugs panel by MGIT is an invaluable tool in tuberculosis treatment, offering an extensive profile of drug susceptibility patterns to guide targeted therapy. By addressing complex and drug-resistant TB cases, this test significantly contributes to improved patient outcomes and supports the ongoing efforts to combat tuberculosis effectively.
The AFB Drug Susceptibility - Comprehensive 13 Drugs Panel is a crucial diagnostic test that evaluates the susceptibility of the Mycobacterium tuberculosis (MTB) complex to 13 different anti-tuberculosis drugs. This test utilises the Mycobacteria Growth Indicator Tube (MGIT) method on pure cultures of MTB, providing valuable insights into the effectiveness of various drugs against a patient's specific strain of MTB, including both first-line and second-line medications. The AFB Drug Susceptibility - Comprehensive 13 Drugs Panel plays a vital role in guiding tuberculosis treatment and identifying potential drug resistance.
By determining the susceptibility of the MTB strain to each of the 13 drugs, doctors can formulate personalised and effective treatment regimens for tuberculosis patients. This is particularly important in cases of drug-resistant tuberculosis, where identifying the most appropriate antibiotics is essential for successful treatment outcomes.
Reasons for Undergoing the AFB Drug susceptibility - Comprehensive 13 drugs panel
There are several scenarios in which a doctor may recommend the AFB Drug Susceptibility - Comprehensive 13 Drugs Panel:
- When a patient exhibits symptoms suggestive of tuberculosis
- When a patient has been diagnosed with tuberculosis and requires drug susceptibility testing to guide treatment
- When a patient has been on anti-tuberculosis treatment but shows signs of treatment failure
- When there is a concern about drug-resistant tuberculosis
- When a patient has a history of non-compliance with tuberculosis treatment
List of parameters considered during the AFB Drug susceptibility - Comprehensive 13 drugs panel
The AFB Drug Susceptibility - Comprehensive 13 Drugs Panel measures the susceptibility of MTB complex to 13 anti-tuberculosis drugs, each providing valuable information:
- Streptomycin, Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide: These first-line drugs are the cornerstone of initial TB treatment. Susceptibility to these drugs indicates whether the standard treatment regimen will be effective.
- Kanamycin, Ethionamide, PAS, Ofloxacin, Capreomycin, Moxifloxacin, Amikacin, and Clofazimine: These second-line drugs are used when there is resistance to first-line drugs or in cases of treatment failure. Susceptibility to these drugs helps formulate alternative treatment regimens.
The test results reveal which drugs the patient's specific strain of bacteria is susceptible to and which ones will be ineffective, guiding the selection of appropriate antibiotics for treating TB.
AFB Drug susceptibility - Comprehensive 13 drugs panel Preparation
To prepare for the AFB Drug Susceptibility - Comprehensive 13 Drugs Panel, patients should:
- Provide a complete medical history, including details of any previous tuberculosis treatment
- Follow any specific instructions given by their doctor
- Inform their doctor of any specific requirements or health conditions
- Have a sample of the MTB complex collected by a doctor, which will then be sent for analysis
AFB Drug susceptibility - Comprehensive 13 drugs panel Results & Interpretation
The results of the AFB Drug Susceptibility - Comprehensive 13 Drugs Panel indicate whether the MTB complex is susceptible or resistant to each of the 13 drugs tested:
- Susceptible: If the organism does not grow in the presence of a particular drug (indicated by growth units <100 in MGIT), it is susceptible to that drug.
- Resistant: If the organism grows in the presence of a particular drug (indicated by growth units ≥100 in MGIT), it is resistant to that drug.
- Abnormal Results: Resistance to certain drugs may indicate drug-resistant TB, which means those specific antibiotics will not be effective in treating the infection. This information is critical for formulating personalised and effective treatment regimens.
Home Collection for AFB Drug susceptibility - Comprehensive 13 drugs panel near you
Metropolis Healthcare offers a convenient home sample collection service for the AFB Drug Susceptibility - Comprehensive 13 Drugs Panel. A trained phlebotomist will visit your home to collect the necessary samples, ensuring your comfort and safety while maintaining high standards of sample handling and testing accuracy. This service allows you to receive timely and reliable results without compromising on the quality of diagnostic solutions. By making healthcare more accessible, Metropolis Healthcare demonstrates its commitment to providing quality diagnostic services conveniently at your doorstep.
AFB Drug Susceptibility Panel - Comprehensive (13 drugs), Pure Culture Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the AFB Drug Susceptibility Panel - Comprehensive (13 drugs), Pure Culture with a clear pricing structure.
The AFB Drug Susceptibility Panel - Comprehensive (13 drugs), Pure Culture Price in Mumbai is ₹ 14,310 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
This test measures the susceptibility of mycobacteria, specifically Mtb complex, to 13 different drugs. The drugs included in this panel are Streptomycin, Isoniazid, Rifampicin, Ethambutol, Pyrazinamide, Kanamycin, Ethionamide, PAS, Ofloxacin, Capreomycin, Moxifloxacin, Amikacin, and Clofazimine.
• To guide healthcare providers in selecting the most appropriate antibiotics for treating tuberculosis
• To determine which drugs the patient's specific strain of bacteria is susceptible to and which ones will be ineffective
• To assess drug resistance and evaluate treatment effectiveness
This test is recommended when • a patient exhibits symptoms of tuberculosis, • a patient has been diagnosed with tuberculosis and requires drug susceptibility testing, • a patient has been on anti-tuberculosis treatment but shows signs of treatment failure, • there is a concern about drug-resistant tuberculosis, or • a patient has a history of non-compliance with tuberculosis treatment.
Abnormal results may indicate drug resistance, which means that certain antibiotics will not be effective in treating tuberculosis infection.
During this test, a healthcare professional will collect a sample of the Mycobacterium tuberculosis (Mtb) complex from your body. They will send the sample for analysis.
• Provide your complete medical history and any previous tuberculosis treatment details.
• Follow any specific instructions given by your healthcare provider, such as fasting requirements or discontinuing certain medications.
• Inform your doctor if you have any specific requirements.
• Acid-fast bacilli smear: This test helps in the initial diagnosis of tuberculosis.
• GeneXpert MTB/RIF: This molecular test detects the presence of Mtb complex DNA and checks for resistance to Rifampicin, a commonly used drug in tuberculosis treatment.
AFB Susceptibility Test for Tuberculosis or Comprehensive Drug Susceptibility Test for Mycobacterium tuberculosis
Tuberculosis (TB) is a contagious bacterial infection caused by the bacteria Mycobacterium tuberculosis. It primarily affects the lungs but can also affect other parts of the body. TB spreads through the air when an infected person coughs or sneezes.
The AFB Drug Susceptibility - Comprehensive 13 Drugs Panel is a diagnostic test that evaluates the susceptibility of the Mycobacterium tuberculosis (MTB) complex to 13 different anti-tuberculosis drugs using the MGIT method on pure cultures of MTB. It helps determine the most effective treatment for tuberculosis.
Home sample collection available for AFB Drug Susceptibility - Comprehensive 13 Drugs Panel. A trained phlebotomist will visit your home to collect the blood sample, ensuring that the sample is handled with the highest standards of care and accuracy.
The test does not measure "levels" but rather indicates susceptibility or resistance to each drug. A "susceptible" result means the drug is effective against the MTB strain, while a "resistant" result indicates the drug is not effective.
The AFB Drug Susceptibility - Comprehensive 13 Drugs Panel guides doctors in selecting the most appropriate antibiotics for treating tuberculosis. It determines which drugs the patient's specific strain of bacteria is susceptible to and assesses drug resistance and treatment effectiveness.
The AFB Drug Susceptibility - Comprehensive 13 Drugs Panel is recommended when a patient exhibits symptoms of tuberculosis, has been diagnosed with TB and needs drug susceptibility testing, shows signs of treatment failure, or has concerns about drug-resistant TB.
There is no specific timing mentioned for this test; it is performed as needed based on clinical indications and your doctor's recommendations.
Fasting is not specifically required for this AFB Drug Susceptibility - Comprehensive 13 Drugs Panel, but you should follow any instructions given by your doctor.
You should provide your complete medical history, follow any specific instructions given by your doctor, and inform them of any specific requirements or health conditions that may be relevant to the test.
The parameters include the susceptibility of MTB to 13 anti-tuberculosis drugs: streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, kanamycin, ethionamide, PAS, ofloxacin, capreomycin, moxifloxacin, amikacin, and clofazimine.
The AFB Drug Susceptibility - Comprehensive 13 Drugs Panel should be done when a patient exhibits symptoms of tuberculosis, has been diagnosed with TB and needs drug susceptibility testing, shows signs of treatment failure, or has concerns about drug-resistant TB.
The AFB Drug Susceptibility - Comprehensive 13 Drugs Panel itself typically takes 5 to 7 days to complete.
The reports for Drug Susceptibility - Comprehensive 13 Drugs Panel are typically available within 4 weeks, based on the day/time when the sample was collected and processed. For exact turnaround time, you can consult with your healthcare provider or the lab.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
WhatsApp